T1	Procedure 0 16	Systemic therapy
T2	Procedure 20 32	radiotherapy
*	OR T1 T2
T3	Temporal 33 62	within 4 weeks prior to Day 1
T4	Reference_point 57 62	Day 1
*	OR T3 T4
T5	Scope 0 32	Systemic therapy or radiotherapy
R1	Has_temporal Arg1:T5 Arg2:T3	
T6	Temporal 64 69	Prior
T7	Procedure 70 77	therapy
T8	Drug 83 125	agents targeting the DR5 apoptosis pathway
*	OR T7 T8 T6
T9	Qualifier 127 132	Major
T10	Procedure 133 151	surgical procedure
T11	Procedure 153 164	open biopsy
T12	Qualifier 169 180	significant
T13	Condition 181 197	traumatic injury
T14	Temporal 198 227	within 4 weeks prior to Day 1
T15	Reference_point 222 227	Day 1
*	OR T14 T15
R2	Has_qualifier Arg1:T13 Arg2:T12	
*	OR T13 T11 T10
R3	Has_qualifier Arg1:T10 Arg2:T9	
T16	Scope 127 197	Major surgical procedure, open biopsy, or significant traumatic injury
R4	Has_temporal Arg1:T16 Arg2:T14	
T17	Mood 232 252	anticipation of need
T18	Qualifier 257 262	major
T19	Procedure 263 281	surgical procedure
R5	Has_qualifier Arg1:T19 Arg2:T18	
T20	Temporal 282 312	during the course of the study
T21	Reference_point 303 312	the study
*	OR T20 T21
R6	Has_mood Arg1:T19 Arg2:T17	
*	OR T16 T19
R7	Has_temporal Arg1:T19 Arg2:T20	
T22	Qualifier 314 319	Other
T23	Condition 320 341	invasive malignancies
T24	Temporal 342 371	within 5 years prior to Day 1
T25	Reference_point 366 371	Day 1
R8	Has_index Arg1:T24 Arg2:T25	
R9	Has_qualifier Arg1:T23 Arg2:T22	
R10	Has_temporal Arg1:T23 Arg2:T24	
T26	Qualifier 379 385	active
T27	Condition 386 402	brain metastases
R11	Has_qualifier Arg1:T27 Arg2:T26	
T28	Temporal 379 385	active
R12	multi Arg1:T26 Arg2:T28	
T29	Qualifier 404 416	Uncontrolled
T30	Condition 417 437	intercurrent illness
T31	Temporal 468 475	ongoing
T32	Qualifier 479 485	active
T33	Condition 486 495	infection
T34	Drug 506 528	parenteral antibiotics
T35	Temporal 529 542	at enrollment
R13	Has_temporal Arg1:T34 Arg2:T35	
*	OR T31 T32
T36	Scope 468 485	ongoing or active
R14	Has_scope Arg1:T33 Arg2:T36	
R15	AND Arg1:T33 Arg2:T34	
R16	Has_qualifier Arg1:T30 Arg2:T29	
T37	Scope 404 437	Uncontrolled intercurrent illness
T38	Scope 468 542	ongoing or active infection requiring parenteral antibiotics at enrollment
T39	Reference_point 532 542	enrollment
R17	Has_index Arg1:T35 Arg2:T39	
R18	Subsumes Arg1:T37 Arg2:T38	
T40	Qualifier 544 566	Clinically significant
T41	Qualifier 568 579	symptomatic
T42	Condition 580 602	cardiovascular disease
T43	Measurement 604 637	New York Heart Association (NYHA)
T44	Value 638 657	Grade II or greater
R20	Has_qualifier Arg1:T42 Arg2:T41	
R21	Has_qualifier Arg1:T42 Arg2:T40	
R19	Has_value Arg1:T43 Arg2:T44	
T45	Condition 658 682	congestive heart failure
R22	AND Arg1:T45 Arg2:T43	
T46	Qualifier 684 691	serious
T47	Condition 692 710	cardiac arrhythmia
R23	Has_qualifier Arg1:T47 Arg2:T46	
T48	Value 712 731	Grade II or greater
T49	Condition 732 759	peripheral vascular disease
T50	Observation 764 774	history of
T51	Qualifier 775 780	major
T52	Procedure 781 794	heart surgery
R24	Has_qualifier Arg1:T52 Arg2:T51	
R25	Has_temporal Arg1:T52 Arg2:T50	
*	OR T49 T52
T53	Temporal 795 819	within 6 months of Day 1
T54	Reference_point 814 819	Day 1
R26	Has_index Arg1:T53 Arg2:T54	
T55	Scope 732 794;856 872	peripheral vascular disease, or history of major heart surgery limit compliance
T56	Observation 856 872	limit compliance
R27	Has_temporal Arg1:T55 Arg2:T53	
T57	Value 910 918	positive
T58	Measurement 923 934	hepatitis C
T59	Measurement 938 965	hepatitis B surface antigen
*	OR T59 T58
T60	Scope 923 965	hepatitis C or hepatitis B surface antigen
R28	Has_value Arg1:T60 Arg2:T57	
T61	Observation 967 974	History
T62	Qualifier 978 983	other
T63	Condition 984 991	disease
R29	Has_qualifier Arg1:T63 Arg2:T62	
R30	Has_temporal Arg1:T63 Arg2:T61	
T64	Condition 993 1014	metabolic dysfunction
T65	Procedure 1016 1036	physical examination
T66	Condition 1016 1044	physical examination finding
R31	multi Arg1:T66 Arg2:T65	
T67	Condition 1049 1076	clinical laboratory finding
T68	Procedure 1049 1068	clinical laboratory
R32	multi Arg1:T67 Arg2:T68	
T69	Mood 1095 1107	suspicion of
T70	Condition 1110 1117	disease
T71	Condition 1121 1130	condition
T72	Condition 1136 1151	contraindicates
*	OR T71 T70
T73	Scope 1110 1130	disease or condition
*	OR T73 T69
T74	Scope 1095 1130	suspicion of a disease or condition
T75	Drug 1162 1182	investigational drug
T76	Observation 1197 1233	affect interpretation of the results
T77	Observation 1250 1281	render the patient at high risk
T78	Condition 1286 1309	treatment complications
*	OR T76 T77
R34	AND Arg1:T77 Arg2:T78	
T79	Scope 1136 1309	contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications
R33	AND Arg1:T72 Arg2:T75	
R35	Subsumes Arg1:T74 Arg2:T79	
T80	Procedure 1318 1341	anticoagulation therapy
T81	Drug 1318 1333	anticoagulation
R36	Subsumes Arg1:T80 Arg2:T81	
T82	Observation 1343 1375	Participation in clinical trials
T83	Observation 1379 1422	undergoing other investigational procedures
T84	Temporal 1423 1452	within 30 days prior to Day 1
T85	Reference_point 1438 1452	prior to Day 1
R37	multi Arg1:T84 Arg2:T85	
*	OR T82 T83
T86	Scope 1343 1422	Participation in clinical trials or undergoing other investigational procedures
R38	Has_temporal Arg1:T86 Arg2:T84	
T87	Condition 1454 1463	Pregnancy
T88	Observation 1467 1481	breast feeding
*	OR T87 T88
T89	Condition 1489 1500	sensitivity
T90	Drug 1504 1553	any of the products administered during the study
T91	Condition 1559 1567	disorder
T92	Negation 1573 1599	compromises the ability of
T93	Measurement 1615 1644	give written informed consent
T94	Procedure 1652 1680	comply with study procedures
*	OR T93 T94
T95	Scope 1615 1680	give written informed consent and/or comply with study procedures
R39	Has_negation Arg1:T95 Arg2:T92	
R40	Has_negation Arg1:T91 Arg2:T92	
